Degraded Antibody Drug Conjugation:
We are also offering a DAC’s synthesis, Linker optimisation using various length and match-pair (PEG/Alkyl/Rigid linkers) with Thalidomide, VHL, Lenalidomide, Pomalidomide follow-by cleavable/non-cleavable linkers with active site in high purity and adequate to allow clients for rapid screening for bio-conjugation and DAR ratio.
DAC’s has several potential advantages over PROTAC such as:
Building on our expertise to support cytotoxic chemistry program and highly potent chemistry, we are also offering to projects in ADC technology as per client requirements such as,
-
It can deliver the degraders with poor physicochemical or DMPK properties in vivo
-
Avoid complex formulations that are often necessary for PROTACs to gain activity upon in vivo exposure
-
Target PROTAC molecules of interest to specific tumours or tissues
Contact Us
Copyright © 2024 Pharmace Research. All Rights Reserved. | Developed by Technotery .